IJRAR.ORG E-ISSN: 2348-1269, P-ISSN: 2349-5138

INTERNATIONAL JOURNAL OF RESEARCH AND ANALYTICAL REVIEWS (IJRAR) | IJRAR.ORG

An International Open Access, Peer-reviewed, Refereed Journal

KOJIC ACID LOADED SOLID LIPID NANOPARTICLES FOR TREATMENT OF HYPERPIGMENTATION

Anees Unnisa[1], J.Rakshitha[2], Lanka Poojitha[3], Totameedi.Sukanya[4], Uppala Anjali[5], Chekkilla Bhargavi*

Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya (co-ed), Tarnaka, Hyderabad.

Correspondence: **Dr.CH.Bhargavi**, M.Pharm., PhD

Assistant professor, Department of Pharmaceutics, Sarojini Naidu Vanitha Pharmacy Maha Vidyalaya.

1.ABSTRACT:

One prevalent dermatological issue that has a big psychological impact is hyperpigmentation disorders. The well-known tyrosinase inhibitor kojic acid has been used extensively to treat hyperpigmentation, but its low skin penetration, poor stability, and possible irritation limit its clinical use. By improving drug stability, controlled release, and targeted skin distribution, solid lipid nanoparticles (SLNs) have become a viable nanocarrier system that can get beyond these restrictions. An extensive summary of solid lipid nanoparticles loaded with kojic acid for the treatment of hyperpigmentation is given in this paper. The paper also emphasizes new developments in kojic acid-loaded SLN synthesis techniques, *invitro* characterisation parameters and therapeutic application of SLNs loaded with kojic acid in the treatment of hyperpigmentation are examined. A rigorous analysis is conducted on the possible benefits of SLNs, such as increased patient compliance, less side effects, and improved bioavailability. Lastly, the present restrictions, safety issues, and prospects for the. The purpose of this review is to give researchers and formulators useful information for creating safe and efficient nanotechnology-based therapies for hyperpigmentation.

KEYWORDS: Hyperpigmentation disorders, Kojic acid, Solid lipid Nanoparticles, Tyrosinase inhibition.

2.INTRODUCTION:

Hyper-pigmentation disorders, marked by excessive melanin production, are commonly treated topically using KA, which acts as a Tyrosinase inhibitor[1,2]. However, the efficacy of KA in topical applications has always been highly limited due to the fact that it is a very hydrophilic compound and shows insufficient permeation through the stratum corneum[1,3]. This poor permeability often may result in drug accumulation on the skin surface, leading to irritation-related adverse events like irritant dermatitis, erythema, and pruritus and limiting its clinical utility[3].

To overcome these formulation challenges and improve the therapeutic efficacy of drugs, Solid Lipid Nanoparticles represent a promising nanocolloidal carrier system[4]. SLNs are organic nanoparticles, often made up of biocompatible, physiological lipids, providing a very effective vector for the advancement of drug delivery[7,8]. Application of SLNs for KA (KA-SLNs) is an emerging technology in lipid research for targeting hydrophilic drugs to the skin for treating hyperpigmentation[8].

A high speed homogenisation followed by ultra-probe sonication method can be used to specifically optimize the preparation of KA-SLNs. The best dispersion, called KA-SLN3, can be prepard using Glyceryl mono-stearate and Cholesterol as lipid excipients, while Span 60 and Tween 20 as co-emulsifiers.

Therefore, the detailed characterization of optimized KA-SLN3 dispersion states it is potential for clinical application. The desired physical properties can be obtained, and the amorphous state of KA would be stabilized, without any chemical interaction between the drug and other ingredients. Moreover, from a functional point of view, the KA-SLN formulation shows controlled release kinetics and higher tyrosinase inhibition activity than pure KA. In addition, in vitro and ex vivo percutaneous absorption studies would confirm that the nanoparticle dispersion successfully improves KA percutaneous delivery and thus represents a novel and potential preparation for hyper-pigmentation treatment[1]. The general advantages of SLNs are increased stability, sustained release, and bioavailability of active ingredients[7].

Advantages of KA-SLN Formulations:

SLNs consist of bio-compatible physiological lipids and enhance drug delivery:

• *Enhanced Delivery and Efficacy:* Loading KA into SLNs is a strategy to enable the hydrophilic drug to bypass the stratum corneum effectively. This mechanism improved the percutaneous delivery of KA and led to more potent tyrosinase inhibition compared with the pure compound[2].

• *Controlled Release:* One of the most important formulation advantages of SLNs is that they achieve controlled release kinetics[1].

• *Stability:* As nanocarriers, SLNs also generally protect the therapeutic molecules against degradation and the harsh biological environment.[5]

Potential Disadvantages Nanoparticles Concerns

Since KA-SLNs are under nanotechnology, they have some safety concerns related to nano-sized materials:

• *Systemic and Cellular Risk:* Small nanoparticles may have the chance of systemic circulation and cellular entry.

• *Toxicity:* Their higher surface-to-volume ratios are associated with greater chemical reactivity, possibly resulting in the production of reactive oxygen species that can damage DNA.

Compromised Skin: While generally innocuous on intact skin, nanocarriers have raised the main concern with respect to their application on broken skin, such as wounds, acne, or eczema[6].

Kojic acid:



Kojic acid (KA) is a natural bleaching agent and a well-known tyrosinase inhibitor produced by fungal species such as Aspergillus and Penicillium. It finds widespread application in cosmetics for hyperpigmentation treatment due to its skin-whitening effects through the inactivation of the tyrosinase enzyme and suppression of melanin production. Furthermore, KA is considered in pharmaceutical applications for antimicrobial, antiviral, and anti-cancer properties. Its hydrophilic nature compromises skin permeability. For this reason, the development of derivatives such as Kojic Acid Dipalmitate commonly formulated in nanocarriers has aimed to enhance its stability and dermal delivery[1-5].

Solid lipid nanoparticles:

Solid Lipid Nanoparticles (SLNs) are an outstanding nanocolloidal drug delivery system, usually made of biocompatible physiological lipids. SLNs are organic nanoparticles that are usually spherical, with a mean diameter usually found within the range of 50 and 1,000 nm. This carrier system possesses a number of advantages, such as improved bioavailability, controlled release kinetics, and enhanced stability of therapeutic agent. They have been considered an emerging technology for targeting drugs, including hydrophilic compounds, to the skin[2,3,4].

3.RATIONALE:

Kojic acid face creams are essential in the treatment of hyperpigmentation disorders, since KA is a potent tyrosinase inhibitor, thus restraining melanin formation. Due to the fact that KA is naturally unstable and poorly absorbed, its derivative, KA Dipalmitate, is highly valued in cosmetics for its superior stability, oil solubility, and low toxicity. Advanced formulations, such as those using Solid Lipid Nanoparticles, are important because of the dermal delivery enhancement seen with SLN-based cream formulations, achieving the maximum KDP concentration in the epidermis layer. The epidermis is a target for such a formulation since the tyrosinase enzyme in melanocytes is there. Therefore, the SLN-based cream represents a proper topical

formulation for the melasma improvement and skin lightening improvement, having enhanced efficacy and safety. Anti-aging outcomes are also present[6-8].

4. THERAPEUTIC USES FOR PARTICULAR HYPERPIGMENTATION CONDITIONS

4.1Melasma

- Prolonged inhibition of melanogenesis
- Improved compliance as a result of less annoyance
- Suitable for long-term administration

4.2 Hyperpigmentation Following Inflammation (PIH)

- Rebound pigmentation is avoided by controlled release.
- Reduced inflammation keeps PIH from getting worse.

4.3 Hyperpigmentation Caused by UV

- SLNs improve kojic acid's photostability
- Preventing and treating sun-induced pigmentation effectively

4.4 Freckles and Age Spots

- Lesions gradually brighten as a result of targeted epidermal administration.

4.5 Formulation Approaches

- SLNs loaded with kojic acid can be used in:
- Creams
- Gels
- Emulgels
- Lotions

Frequently paired with:

- Sunscreen
- Antioxidants (vitamins C and E)
- Additional depigmenting substances (niacinamide, arbutin) [3,4]

5.METHODS OF PREPARATION

KA cream can be made in many ways, few of which are as follows;

Method 1

This method utilizes high-speed homogenization followed by ultra-probe sonication to create a highly stable colloidal dispersion suitable for topical delivery.

Component	Function	Nature
Kojic Acid	Depigmenting agent	Hydrophilic
Glyceryl Monostearate	Emulsifier, thickener, stabilizer	Solid Lipid
Cholesterol	Moisturizer and emollient	Solid Lipid excipient
Oleic acid	Emolient , penetration enhancer	Liquid lipid excipient
Span 60	Co-emulsifier	Lipophillic surfactant
Tween 20	Surfactant, co-emulsifier	Hydropholic surfactant
Water	solvent	Aqueous phase

Procedure:

1. **Preparation of Phases:** Melt the **lipid phase** (GMS, Chol, OA, and Span 60) together by heating to 95°C. Homogenize the **aqueous phase** (deionized water and Tween 20) using a high-shear homogenizer and simultaneously heat to 95 °C.
2. **Emulsion Formation:** Place one-third of the aqueous phase (heated) immediately in an ice-water bath. Add the remaining two-thirds of the aqueous phase containing the dissolved **Kojic Acid (KA)** drop wise to the melted lipid phase.
3. **Sonication:** The mixture can now be subjected to **probe sonication** using a probe sonicator at 100% amplitude for 5 minutes.
4. **Cooling and Final Sonication:** After the first sonication, add the reserved one-third portion of the cooled aqueous phase into the mixture to form a pre-emulsion. Place this mixture in an ice-water bath and sonicate again for 5 minutes before finally cooling to room temperature (22 °C).[4]

Method 2

This technique uses a similar probe sonication method tailored for Solid Lipid Nanoparticles, designed to enhance the effectiveness and percutaneous delivery of KA.

kojic acid	Depigmenting agent (active drug)
GMS	Stabilizer, thickener
cholesterol	Moisturizer
Tween 20	Hydrophilic Surfactant
Span 60	Lipophilic Surfactant
Water	Solvent

Procedure:

1. **Phase Heating:** Mix the **lipid phase** (GMS, Chol, and Span 60) and heat it at 95 °C. Homogenize the **water phase** (Deionized water and Tween 20) and also heat at 95 °C.
2. **Phase Mixing and High-Intensity Sonication:** Now cool one-third of the water phase (containing Tween 20) in an ice-water bath. A mixture of KA and the remaining two-thirds of the preheated water phase is to be added dropwise to the lipid phase. Immediately subject this combined mixture to high-intensity probe sonication (100% amplitude) for 5 minutes.
3. **Cooling and Final Sonication:** Now add the remaining one-third of the cooled water phase to the mixture to form an initial pre-emulsion, which is then to be placed in an ice-water bath. The mixture should be subjected to sonication again for 5 minutes (or 30 minutes in some studies) and then transfer to an ice bath to cool.[8]

Method 3

This method employs solvent evaporation in combination with high-speed homogenization to encapsulate the lipophilic derivative KAD, yielding small nanoparticles.

Kojic acid	Depigmenting agent
GMS	Stabilizer, thickener
Polyvinyl alcohol	Emulsifier
Organic solvent (ethanol/acetone)	vehicle

Procedure:

1. **Dissolving the Drug:** First dissolve the KAD in the organic solvent (ethanol/acetone mixture).
2. **Mixing with Lipid Phase:** Mix this solution with the melted **GMS** (lipid phase) at approximately 75 °C.
3. **Emulsification:** Slowly add the resulting solution to the 2% PVA aqueous solution. Then subject the mixture to **homogenization** at high speed (around 15,000 rpm) for 20 minutes.
4. **Solvent Evaporation:** The organic solvent in the resulting emulsion is removed by evaporation (using a rotary evaporator) for 20 minutes to yield the KAD-SLN dispersion.[1]

Method 4

This method describes preparing the final topical dosage form (cream) by integrating the pre-prepared solid lipid nanoparticles (from Method 3, for example) into a standard oil-in-water (o/w) vanishing cream base.

Kojic acid	Depigmenting agent
Water	vehicle
Potassium hydroxide	Stabilizer
Sorbitol solution	Humectant
Stearic acid	Emollient, emulsifier
Light mineral oil	Base / emollient

Procedure:

1. **Phase Heating:** Take the lipid phase and the aqueous phase components and heat separately to 65 °C.
2. **Emulsion Mixing:** Now slowly add the heated water phase to the heated lipid phase while stirring to form the cream emulsion base.
3. **Active Ingredient Addition:** Depending on the formulation desired, add either KAD powder or the pre-prepared **SLN loaded with KAD** to the emulsion once the temperature has cooled to 50 °C.
4. **Congealing:** Cool down the resulting formulation to congeal, forming the final SLN-based KAD cream.[3]

Method 5

This method focuses on encapsulating Kojic Acid Dipalmitate (KAD) within ethosomes (highly stable vesicles containing high concentrations of ethanol), typically prepared using the cold method, to improve skin penetration.

Kojic acid	Depigmenting agent
Soy phosphotidylcholine	Vesicle former
Ethanol	Solvent, penetration enhancer
Propylene glycol	Humectant
Water	Aqueous phase
Carbopol	Gelling agent
Glycerol	Humectant

Procedure:

1. **Suspension Preparation (Cold Method):** Prepare the ethosomal suspensions loaded with KAD by mixing KAD, soy phosphatidylcholine, high concentration ethanol, propylene glycol, and water. The optimized resulting suspension should exhibit characteristics like a small size (e.g., 148 nm) and high entrapment efficiency (e.g., 90.0008%).
2. **Gel Base Preparation:** To convert the suspension into a topical gel, weigh the components like 10% glycerol, a gelling agent (e.g., 2%), and distilled water (up to 100%) into a beaker.

3. **Final Mixing:** Stir this gel base at approximately 500 rpm for 5 minutes. Finally, add the pre-prepared **KAD-loaded ethosomal suspension** under continuous stirring to create the final ethosomal gel formulation[4].

6.EVALUATION TESTS :

Colour and Appearance :

The colour of the formulation is one of the key physical stability parameters that one must monitor in storage studies. In KA preparations, pure KA is light-sensitive, heat-sensitive, and prone to oxidation, which can be indicated by yellow or brown discoloration. Change in colour should be examined in the course of stability study. Nanoemulsion preparation of KA should not indicate any signs of creaming or cracking and phase separation during thermal stability study, confirming stability and appropriate appearance of the preparation[5].

pH :

The pH of the cream or gel represents a critical quality control parameter, usually determined with the help of a calibrated pH meter. It has to be kept at an appropriate level - such as 5.5-6.0 for a given formulation-, hence requiring the addition of an acidifying agent (citric acid) or a base (such as NaOH). pH is also to be controlled during time -with the stability study.

Viscosity :

The viscosity of the preparation can be determined, usually by a Brookfield viscometer.It is a critical factor in preparation of KA loaded SLN cream, as it directly impacts the long term stability, efficacy and consistency.The cream should have the viscosity ranging between 2,000-50,000 cps.[4]

Spreadability :

Spreadability of the final gel or cream determines its applicability and user-friendly attributes. The modified apparatus consisting of two glass plates and weights can be employed, and it measures the time for slides to separate, that is proportional to the stiffness of the formulation.
Place the cream between two galss slides and place a weight on top of slides for 5 minutes. The time it takes to separates the slides is measured to determine the spreadability.

S=ml/t
Where,
S= spreadability in gm.cm/sec
M=weight kept on upper slide
L=length of glass slide
T=time in seconds.

Stability and Phase Separation :

Stability studies are an important part of nanocarrier formulations, and this is particularly true since KA is highly susceptible to degradation (oxidation, light, heat). Stability is usually evaluated under accelerated conditions, such as at 40 °C, at ambient temperature (25 °C or at room temperature), and under refrigerated conditions at 4 °C or 2 °C-8 °C, monitored for 3-6 months[2].

Physical Stability Monitoring:

Stability encompasses monitoring several parameters over time, which include color, pH, viscosity, and general physical appearance, such as absence of precipitation or particle aggregation. In this regard, stability studies of KA-SLN dispersion monitored size, PDI, ZP, and EE%. Normally, the ideal storage temperature for SLNs is 4 °C, since at higher temperatures particle growth and subsequent destabilization occur[6].

Irritancy:

Mark the area of the skin to be evaluated. Apply the cream on the marked area and check for any irritant, erythema and edema for upto 24 hours.[4,6]

Greasiness and Washability :

Current sources indicate that KDP is an important component of most creams for its enhancement of the silky feel of the finished product. Shea butter, commonly added in most KA creams, strengthens skin lipids and enhances smoothness and texture.
Apply the cream on the skin to determine if it is greasy or oily.[2]

7.CONCLUSION :

Kojic acid (KA) is a well-established depigmenting agent due to its potent tyrosinase inhibitory activity. Its intrinsic physicochemical disadvantages, such as instability when exposed to light, heat, and oxygen, poor skin absorption because of its hydrophilic nature, and the possibility of negative side effects after topical treatment, restrict its therapeutic and cosmetic use. KA and its more stable, oil-soluble derivative, kojic acid dipalmitate (KDP), have been added to sophisticated nanocarrier systems like nanoemulsions, solid lipid nanoparticles (SLNs), and nanostructured lipid carriers (NLCs), which are made using methods like homogenization and sonication, in order to get around these restrictions and improve therapeutic efficacy in hyperpigmentation disorders like melasma and facial dyschromia. Among them, SLNs have several noteworthy benefits, such as greater skin penetration, regulated release, better drug stability, and efficient localization inside the viable epidermis. KA-loaded SLNs are especially well suited for long-term management of hyperpigmentation, where sustained efficacy and few side effects are crucial, due to their biocompatibility and superior tolerability. Further clinical and translational research is required to establish standardized formulations, long-term safety, and therapeutic efficacy, even if the literature now in publication indicates their promise. All things considered, KA-loaded SLN-based topical formulations offer a potential platform for upcoming medicinal and cosmetic uses.

Abreviations: Kojic acid - KA, kojic acid dipalmitate - KAD, Solid lipid nanoparticles - SLNs, Nano emulsions - NE.

REFERENCES:

[1]. Khezri K, Saeedi M, Morteza-Semnani K, Akbari J, Rostamkalaei SS. An emerging technology in lipid research for targeting hydrophilic drugs to the skin in the treatment of hyperpigmentation disorders: kojic acid-solid lipid nanoparticles. *Artificial Cells, Nanomedicine, and Biotechnology*. 2020 Jan 1;48(1):841-5312.

[2]. Mohamed EM, Younes AH, Hussein GM. Efficacy of 577 nm pro-yellow laserin the treatment of melasma: a prospective split-face study. *Journal of Cosmetic Laser Therapy*. 2020;22(2):107-103.

[3]. Roselan MA, Ashari SE, Faujan NH, Mohd Faudzi SM, Mohamad R. An improved nanoemulsion formulation containing kojic monooleate: optimization, characterization and in vitro studies. *Molecules*. 2020;25(11):26164.

[4]. Souto EB, Baldim I, Oliveira WP, Rao R, Yadav N, Gama FM, et al. SLN and NLC for topical, dermal, and transdermal drug delivery. *Expert Opinion on Drug Delivery*. 2020;17(3):357-775.

[5]. Mohammadi F, Giti R, Meibodi MN, Ranjbar AM, Bazooband AR, Ramezani V. Preparation and Evaluation of Kojic Acid Dipalmitate Solid Lipid Nanoparticles. *Journal of Drug Delivery Science and Technology*. 2021;61:10218367.

[6]. Khezri K, Saeedi M, Morteza-Semnani K, Akbari J, Hedayatizadeh-Omran A. A promising and effective platform for delivering hydrophilic depigmenting agents in the treatment of cutaneous hyperpigmentation: kojic acid nanostructured lipid carrier. *Artificial Cells, Nanomedicine, and Biotechnology*. 2021;49(1):38-478.

[7]. Tanveer N, Khan HM, Akhtar N. Whitening effect of kojic acid dipalmitate loaded nanosized ethosomal gel for the treatment of hyperpigmentation: in vitro and in vivo characterization. *Journal of Cosmetic Dermatology*. 2022;21(12):6850-629.

[8]. Phasha V. Review on Kojic acid—A skin-lightening ingredient. *Cosmetics (MDPI)*. 2022;9(2):3710.

[9]. Darekar, R. M., Kale, K. K., Lokhande, V. Y., & Karande, K. M. (2025). Kojic Acid in Modern Dermatology: Advances in Delivery Systems, Combinatorial Therapies, and Biotechnological Synthesis for Enhanced Skin Health. International Journal of Pharmaceutical Science and Health Care (IJPHC), 15(5), 31-45.

[10]. Tangau, M. J., Chong, Y. K., & Yeong, K. Y. (2022). Advances in cosmeceutical nanotechnology for hyperpigmentation treatment. Journal of Nanoparticle Research, 24(8), 155.

[11]. Hakim, N. Y. D. L., Singh, H. K. A/P J., Nien, H. K., Hui, M. S., & Wei, L. Z. (2023). Kojic Acid and Kojic Acid Ester: Review on Nanotechnology-based Approach for Enhancing the Delivery Efficacy. Recent Advances in Drug Delivery and Formulation.

[12]. Shahraki, O., & Daneshmand, S. (2023). Solid Lipid Nanoparticles as an Efficient Delivery System for Natural Skin Care Cosmetics: A Review. Research in Molecular Medicine, 11(1).